Nathan Connell: Why Prophylaxis in vWD Has Historically Lagged Behind Established Practice in Hemophilia
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on Linkedln about a recent article he and his colleagues co-authored, adding:
“I’m pleased to share our recent paper, ‘Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?’ published in Therapeutic Advances in Hematology.
It was a privilege to work on this with Robert Sidonio, Fernando Corrales-Medina, Jill Johnsen, Michelle Sholzberg, and Caroline Malcolmson.
In this review, we examine why prophylaxis in von Willebrand disease has historically lagged behind established practice in hemophilia, despite a substantial bleeding burden in patients with severe and recurrent disease.
We discuss barriers to broader implementation, review emerging clinical evidence supporting prophylactic VWF replacement, and argue that the field is moving toward a more individualized, phenotype-driven approach that may help bring VWD care closer to parity with hemophilia.
Recent prospective data and regulatory progress suggest that prophylaxis should be considered more systematically for appropriately selected patients.
Thank you to Octapharma for supporting the medical writing assistance for this publication.”
Title: Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?
Authors: Robert F. Sidonio Jr., Fernando F. Corrales-Medina, Jill M. Johnsen, Michelle Sholzberg, Caroline Malcolmson, Nathan T. Connell
Read the Full Article on Therapeutic Advances in Hematology
Other posts featuring Nathan Connell on Hemostasis Today.
-
May 27, 2026, 13:10Amos Gitonga M: Global Partnerships Supporting Hemophilia and Sickle Cell Care in Africa
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK